{"DataElement":{"publicId":"6290004","version":"1","preferredName":"Liquid Enzalutamide Formulation Not Finish Taking Reason","preferredDefinition":"Text to describe the reason why the patient did not complete taking the liquid enzalutamide formulation.","longName":"EZLTMD_LQ_NCOMP_RSN","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"6289602","version":"1","preferredName":"Liquid Dosage Form Enzalutamide Negation Finish Take","preferredDefinition":"A state of substance that is an intermediate one entered into as matter goes from solid to gas; liquids are also intermediate in that they have neither the orderliness of a crystal nor the randomness of a gas. (Note: This term should not be used to describe solutions, only pure chemicals in their liquid state.)_An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance._An operation in which a term denies or inverts the meaning of another term or construction._Use up completely._As pertains to a medication: ingest, inhale, instill, or inject.","longName":"6289595v1.0:6289600v1.0","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"6289595","version":"1","preferredName":"Liquid Dosage Form Enzalutamide","preferredDefinition":"A state of substance that is an intermediate one entered into as matter goes from solid to gas; liquids are also intermediate in that they have neither the orderliness of a crystal nor the randomness of a gas. (Note: This term should not be used to describe solutions, only pure chemicals in their liquid state.):An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","longName":"C42953:C71744","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Liquid Dosage Form","conceptCode":"C42953","definition":"A substance in the fluid state of matter having no fixed shape but a fixed volume.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Enzalutamide","conceptCode":"C71744","definition":"An orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, enzalutamide inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C53345D-21C0-5FD8-E053-F662850AB836","latestVersionIndicator":"Yes","beginDate":"2018-05-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-05-16","modifiedBy":"ONEDATA","dateModified":"2018-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6289600","version":"1","preferredName":"Negation Finish Take","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.:Use up completely.:As pertains to a medication: ingest, inhale, instill, or inject.","longName":"C25594:C64943:C65105","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Finish","conceptCode":"C64943","definition":"Use up completely.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Take","conceptCode":"C65105","definition":"As pertains to a medication: ingest, inhale, instill, or inject.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C533337-4E19-5FC4-E053-F662850A1F12","latestVersionIndicator":"Yes","beginDate":"2018-05-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-05-16","modifiedBy":"ONEDATA","dateModified":"2018-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435018","version":"1","preferredName":"Clinical or Research Activity","preferredDefinition":"Any specific activity undertaken during the course of a clinical study or research protocol.","longName":"C16203","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741AE5B-831E-25C7-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C533337-4E2A-5FC4-E053-F662850A1F12","latestVersionIndicator":"Yes","beginDate":"2018-05-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-05-16","modifiedBy":"COOPERM","dateModified":"2018-05-17","changeDescription":"Created for 18C0070 Tolerability Assessment of Liquid 5.10.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5270077","version":"1","preferredName":"Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"Reason","context":"DCP","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2240632","version":"1","preferredName":"Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"C25638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F9FA7953-8391-043D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-30","endDate":null,"createdBy":"PWEST","dateCreated":"2005-06-30","modifiedBy":"ONEDATA","dateModified":"2005-06-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"330E255F-7C45-6B7E-E050-BB89AD4313D1","latestVersionIndicator":"Yes","beginDate":"2016-05-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-05-17","modifiedBy":"ZHANGWE","dateModified":"2016-07-08","changeDescription":"5/17/16 created for DCP","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"If no, why did you not comple","type":"Preferred Question Text","description":"If no, why did you not complete taking the medication?","url":null,"context":"CCR"}],"origin":"CCR:Center for Cancer Research","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C56AF06-A18B-78A3-E053-F662850A65FB","latestVersionIndicator":"Yes","beginDate":"2018-05-16","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-05-16","modifiedBy":"COOPERM","dateModified":"2018-05-17","changeDescription":"Created for 18C0070 Tolerability Assessment of Liquid 5.10.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}